Best of ASCO - 2014 Annual Meeting



New Targets and New Technologies (non-IO)

Developmental Therapeutics and Tumor Biology (Nonimmuno)

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
A comparative analysis of RNA sequencing methods with ribosome RNA depletion for degraded and low-input total RNA from formalin-fixed and paraffin-embedded samples.

Xiaojing Lin


A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.

Elizabeth Ruth Plummer


A general approach to optimizing tumor treating fields therapy.

Zeev Bomzon


A novel function for cyclin D1 as a transcriptional role in oncogenesis and tumor development by ChIP-Seq and RNA-Seq.

Yudi Xiong


A novel mutant-allele capture method for enrichment of low abundant cancer mutants.

Rui Lin


A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients.

Priya Kumthekar


A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors.

Erkut Hasan Borazanci


A phase I open label study evaluating VT1021 in patients with advanced solid tumors.

Michael Cieslewicz


A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.

Patrick Schoffski


A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).

Mihaela C. Cristea


A phase I study of the APE1 protein inhibitor APX3330 in patients with advanced solid tumors.

Safi Shahda


A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.

Melissa Lynne Johnson


A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.

Udai Banerji


A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.

Kyriakos P. Papadopoulos


A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor, and LY3023414, a dual inhibitor of class I phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) in patients with advanced solid tumors.

David S. Hong


A randomized phase 0 trial of the mitochondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC).

Miguel Quintela-Fandino


A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies.

Mohammad Telfah


ABT-806 derived antibody drug conjugates (ADCs) inhibit growth of malignant mesothelioma in-vivo.

Puey Ling Chia


AcornFusion: A novel tool to detect gene fusion events in DNA-Seq data.

Lifang Yao


Bioinformatic inspired nanoparticles engineered for enhanced delivery to the bone.

Andrew Gdowski


c-AMP/MAPK dysregulation and its impact on survival and response to immunotherapy in advanced melanomas.

Rami Al-Rohil


Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer.

Atsushi Takano


Combination mTORC1/2 and BCL- XL inhibition in endocrine and CDK4/6-resistant estrogen receptor-positive breast cancer.

Sarah Sammons


DDP4 inhibitors as novel agents in improving survival in diabetic patients with CRC and lung cancer: A SEER-Medicare study.

Rohit Bishnoi


Design, engineering, and characterization of a novel long-acting (Pegylated) single isomer human arginase for arginine depriving anticancer treatment.

Kuo-Ming Yu


Differentiated pharmacokinetic and pharmacodynamic properties of a highly selective MET kinase inhibitor, OMO-1: Implications for efficacy and safety.

Timothy Pietro Suren Perera


Distinct radiological patterns of drug-induced pneumonitis (R-DIP) in early-phase clinical trials and predictive factors affecting outcome: A 10-year systematic review from the Royal Marsden Hospital Phase I Drug Development Unit experience.

Angelika Terbuch


Effect of PGK1 on radiosensitivity through regulation of CIN and CFL1 in human glioma cells.

Hongyi Liu


Effect of therapeutic GAS6/AXL inhibition of tumor and stromal cells on DNA damage and response to chemotherapy in ovarian cancer.

Mary M Mullen


Effect on tumor growth by TGF-β1/COX-2 siRNA combination product (STP705) in a human cholangiocarcinoma (HuCCT-1) xenograft tumor model in nude mice.

Michael Molyneaux


Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.

Olivia Le Saux


FGFR2: A pan-genomic target.

Russell Madison


First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using 89Zr-Df-CPC634 PET/CT.

Iris H.C. Miedema


First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.

Jeeyun Lee


First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.

Judy Sing-Zan Wang


First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

Johann S. De Bono


FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology.

David Michael Hyman


Identification of new targets and biomarkers in lung cancer.

Ioannis Papasotiriou


Impact on U251 glioma cell radiosensitivity and CFL1 level via inhibiting cell motility regulator ROCKII of RhoA-RockII-CFL1 pathway.

Mengjie Zhao


Implication of DYRK1B kinase in dormant glioblastoma cancers and utilization of DYRK1B inhibitors as a novel therapeutic strategy for glioblastoma.

Maria Vilenchik


Innovative dual system for selective eradication of cancer cells using exosomes carrying natural bacterial toxin-antitoxin (TA).

Shiran Shapira


Integrating CRISPR screening with tumor genomic analyses to identify therapeutic targets in hepatocellular carcinomas (HCC) independent of P53.

Ankur Sheel


Mechanistic study of the superior anti-cancer properties of a first-in-class small molecule targeting PCNA.

Long Gu


Meta-analysis of toxicity data in thoracic and abdominal malignancies from: Clinical trials in tumor treating fields.

Ignace Vergote


Molecular biology and treatment strategies for non-V600 BRAF-mutant NSCLC.

Marcelo Vailati Negrao


Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC).

Katia Khoury


Nanoparticle entrapped docetaxel (CPC634) enhances intratumoral docetaxel exposure compared to conventional docetaxel (Cd) in patients with solid tumors.

Florence Atrafi


NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.

Anita Ahmed Turk


Non-inferiority of a new advanced dry plasma thawing system compared to leading standard method: Preservation of coagulation and anticoagulation proteins necessary for use in the clinic.

Farideh Z. Bischoff


Oncology precision medicine for hepatobiliary and pancreatic cancer: An institutional review.

Geoffrey Bellini


Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients.

Hao Xie


Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma.

Lorena Farinas-Madrid


Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Marwan Fakih


Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.

Mark J. Ratain


Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL).

Victor Moreno


Phase I study of procaspase activating compound -1 (PAC-1) in combination with temozolomide (TMZ) for the treatment of recurrent malignant glioma.

Martin Kelly Nicholas


PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.

Juanita Suzanne Lopez


Pooled analysis of onapristone extended release (ONA ER) in metastatic cancer patients (pts): A review of liver safety.

Paul H. Cottu


Preclinical studies evaluate pivotal TNFα nanomedicine clinical trial design.

Naris Nilubol


Preclinical testing of ultra-rapid FLASH total abdominal irradiation demonstrates survival benefit and decreased gastrointestinal toxicity compared to conventional external beam radiation.

Karen Levy


Prognostic significance of amplifications of stemness genes in primary luminal breast cancer depending on the response to neoadjuvant chemotherapy.

Polina Kazantseva


Real-world application of next generation sequencing to guide therapeutic options in lymphoma.

Molly Tokaz


RERG involvement in the RAS pathway and ER-dependent transcription in breast cancer.

Pei-Chen Hsu


Role of ultrasound contrast agent in a tertiary cancer center: Experience in 75 patients with liver biopsy.

Amir Ata Rahnemai-Azar


SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors.

David S. Hong


Targeting the p300/CBP interactome through blockage of the CH1-domain triggers tumor regression in AR-positive and AR-negative xenograft models of castration-resistant prostate cancer (CRPC).

Valentino Cattori


The chick embryo chorioallantoic membrane assay: In ovo model for personalized assessment and evaluation of the most effective therapeutic approach in cancer therapy.

Shiran Shapira


The Circulating Cell-free Genome Atlas (CCGA) Study: Size selection of cell-free DNA (cfDNA) fragments.

Darya Filippova


The landscape of RET alterations from 56,970 adult patients with cancer: Clinical implications.

Alexander Andreev-Drakhlin


Thyrointegrin αvβ3 nano targeted delivery of chemotherapy into solid tumors and its microenvironment.

Dhruba J. Bharali


TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid malignancies with FGFR alterations identified by circulating tumor DNA.

Tomoko Jogo


Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Final results of the phase 1/2 TREAT-ME-1 trial.

Jobst C. von Einem


Unlocking PARP inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform inhibitor efficacy for HRD-negative cancers using the alphalex tumor targeting platform.

Ranjit Bindra


Utilizing data from patient-derived xenograft mouse models of human tumors to inform clinical decision making in Molecular Tumor Boards (MTB) deliberations.

Jens Rueter